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Mesoporous CoNi@Au core@shell nanorods were synthesized as magnetic drug nanocarriers 
by electrodeposition using ionic liquid-in-aqueous microemulsions. Mesoporous nanorods 
present a highly effective area (186 m2 g-1) and magnetic character that allows their 
manipulation, concentration and retention by applying a magnetic field. The nanorods have 
been functionalized with thiol-poly(ethyleneglycol) molecules and molecules of Irinotecan 
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(CPT-11), a drug used in chemotherapy, were retained in both the lattice of the linked thiol-
poly(ethyleneglycol) molecules and inside the interconnected nanorods pores. The nanorods’ 
mesoporous character allowed a high drug-loading capability and magnetic behavior that 
allowed the drug’s controlled release. 
A high cellular viability of HeLa cells was obtained after their incubation with the nanorods 
functionalized with thiol-poly(ethyleneglycol). However, when the nanorods functioned as 
carriers for CPT-11, significant cell death was occurred when the HeLa cells were incubated 
with the functionalized, drug-loaded, nanorods. Cell death also occurred by applying an 
alternating magnetic field, given the effect of both the carrier’s CPT-11 release and the 
mechanical damage of cells by the nanorods under the magnetic field effect. Our proposal to 
used mesoporous magnetic nanorods as drug carriers could thus dramatically reduce the 
amounts of the nanocarrier and the drug needed to efficiently destroy cancer cells.  
 
 
1. Introduction 
 
 
Different types of nanomaterials - polymeric micelles, dendrimers, liposomes, nanoparticles, 
and nanorods, among others- have been proposed as drug delivery systems (DDSs) and, in 
recent decades, have been studied extensively as powerful tools to improve therapeutic efficacy. 
[1] More recently, intensive research has sought to design novel smart nanocarriers of drugs to 
control therapeutic outcomes, target modalities toward specific diseases, and minimized side 
effects.[2]  The effect of the drug delivery system on the activity, localization, and tumor 
accumulation of different drugs has been investigated. Thus, we have already procured 
liposomes, micelles and other solubilizing products to carry photosensitizers for photodynamic 
therapy and camptothecins for chemotherapy, and their usefulness has been assessed by using 
healthy and cancerous cell lines, for in vitro experiments, and DBA/2 tumor bearing mice, for 
in vivo assays. [3] By extension, researchers have also explored using environmentally 
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responsive smart nanocarriers that can improve pharmacological efficacy due to 
physicochemical changes that occur during exposure to external stimuli. These stimuli, which 
can be combined to further enhance pharmacologic activity, include light, temperature, 
ultrasound, magnetic field, electrical field, and chemical signals such as pH, ionic strength, 
redox potential, and enzymatic activities. [4] Using nanocarriers combined with external or 
internal stimuli improve the control of drug delivery over that of traditional release systems in 
vivo (i.e., passive delivery programed prior to implantation) that cannot be modified when the 
needs of therapeutic change. As such, nanomaterials have the potential to revolutionize the 
diagnostic and therapy of cancer, one of the world’s most devastating diseases. They could be 
of particular use with colorectal cancer (CRC), the third most common cause of cancer deaths 
among both men and women in the United States and Europe, as well as the second most 
common lethal cancer overall. [5]  
Current cancer treatments involve surgical intervention, radiation, and chemotherapy, typically 
accompanied by toxic side effects that limit the drug dosage that can be given to a patient, since 
not all the tumor tissue can be exposed to a lethal dose of the drug. [6] In the last decade, several 
new cytotoxic agents have been explored for colorectal cancer treatment. Among them, 
irinotecan (CPT-11), a water-soluble semisynthetic camptothecin derivative of the 
Topoisomerase I family of interactive compounds, is used in current chemotherapy protocols 
for a range of tumor diseases. [7] Such findings are important, because using nanostructured 
materials as carriers can significantly improve the pharmacological properties of drugs, by 
encouraging the drug’s accumulation in the target tissue. Their unique properties can also 
enhance therapeutic efficacy with the application of specific external stimuli, which as triggers 
in drug delivery systems enable a spatially, temporally, or even spatiotemporally controlled 
release that  can play a major role in sustained release systems. [8]  
At the same time, designing carriers capable of selectively releasing their payloads at target 
sites in the body has special relevance in drug delivery systems. Special attention was given to 
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receptor mediated delivery systems, in particular, those targeted to folate receptor that has been 
shown to increase the uptake of the entrapped drugs by folate receptor positive cells. [9] In that 
context, magnetic nanocarriers represent a promising opportunity because they can be 
concentrated and kept with an external field. [10] In recent years, increased efforts have been put 
toward developing magnetic nanomaterials for nanobiomagnetic applications, including the use 
of magnetic resonance imaging contrast agents, targeted drug delivery, bioseparation, and 
magnetically induced hyperthermia. [10, 11] Those applications are possible because magnetic 
nanomaterials, especially magnetic nanoparticles, can be remotely manipulated by magnetic 
fields. Crucial to such biological applications is a quasi-zero magnetization remanent state, 
which prevents the magnetic agglomeration of nanomaterials by virtue of their interaction with 
remanent moments, which in turn stabilizes the nanomaterial’s suspension. [12] By extension, 
surface functionalization could be used to minimize their aggregation. [13] Via hyperthermia or 
mechanical destruction of cells, magnetic nanomaterials can furthermore be heated or rotated, 
respectively, under alternating fields during cancer therapy. [14] Altogether, the integration of 
magnetic materials with biological molecules into chemotherapy can generate smart hybrid 
materials with promising advanced properties.  
Herein, we propose the synthesis of magnetic mesoporous CoNi@Au core@shell nanorods, 
100 nm in diameter and approximately 2 μm in long, by electrodeposition using ionic liquid-
in-aqueous solution (IL/W) microemulsions that can be used as smart drug nanocarriers. The 
objective of this study was to obtain intelligent drug nanocarriers that met four criteria: First, 
nanorod shape and high density of interconnected mesopores needed to offer a surface area 
conducive to supporting high quantities of drugs. Second, magnetic actuation needed to 
radically enhance therapeutic efficacy by allowing easy manipulation, magnetic targeting, 
mechanical destruction and better control of drug release by way of high saturation 
magnetization (Ms) and low remanence (Mr). Third, low cytotoxic effects and high 
biocompatibility were needed to achieve high cellular viability in the presence of carriers. 
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Fourth, the nanocarriers needed to demonstrate ease of functionalization, retention, and release 
of drugs. To test the applicability of nanocarriers, the CPT-11 drug was analyzed for its 
retention and posterior release from the nanocarrier, in magnetic stirring and non-stirring 
conditions. The high surface area and the high drug-loading capability of the CoNi@Au 
mesoporous nanorods, the controlled release of the drug by means of a magnetic field, the 
uptake of the nanorods in the interior of the test HeLa cells and the cellular death of the test 
cells by both the release of the carcinogenic drug and the mechanical destruction of the cells by 
the rotating magnetic field applied make the new nanostructures excellent candidates for 
increased therapeutic efficiency. In sum, the findings of our study could contribute to reducing 
the amount of drug nanocarriers in a therapeutical treatment and thus bringing about more 
efficient carcinogenic cell destruction.  
 
2. Results and Discussion 
 
This paper presents the possibility of using magnetic compact or mesoporous nanorods as 
nanocarriers for drugs. In biomedical applications, nanorods offer advantages over other 
magnetic nanostructures, including higher magnetic moments per unit of volume and larger 
surface-to-volume ratios, especially in the case of mesoporous rods. Although Fe and Ni 
nanorods have been proposed for some biomedical applications, [15] we propose using 
CoNi@Au nanorods, largely because they present high Ms and improved chemical stability. 
[13b, 16] In doing so, we acknowledge the well-known fact that the toxicity of such materials, 
dependent on their contents in biological media, is extremely low and can be eliminated from 
the body in a relatively short time. [10] Moreover, the formation of a gold shell over the entire 
surface of the nanorods prevents the dissolution of the metals, while the functionalization of 
core@shell nanorods with long PEG molecules makes them hydrophilic and minimizes their 
aggregation. Ultimately, we propose the synthesis of new nanorods as drug carriers for 
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pharmacologic treatments in cancer therapy. Along with the functionalization of drug-loaded 
nanorods, using these devices would make it possible to deliver specific drugs to tumor tissues 
by way of a magnetic field, which would dramatically increase the benefits of treatment  
2.1. Nano-carriers Fabrication and Characterization 
Electrodeposition in potentiostatic conditions was used as a synthetic route for preparing 
mesoporous and compact nanorods, using microemulsions with ionic liquids and aqueous 
solutions as electrochemical media, respectively. [17] After synthesis and washing, the magnetic 
nanorods were immersed in a gold salt solution to form a gold shell by galvanic displacement 
under ultrasound stirring. Synthesis is illustrated in Figure 1. We combined the use of a soft 
template (i.e., microemulsion) for pore definition and a hard template (i.e., polycarbonate 
membranes) for nanorods growth in order to control of the length, diameter and pore size by 
way of controlling the deposition time, hard template type, and the microemulsion structure, 
respectively. Notably, this method affords mesoporous or compact nanorods of numerous 
metallic and compositions, all by controlling the composition of the aqueous solution and 
selecting the deposition potential.  
Earlier, to electrodeposit nanorods inside the polycarbonate membranes, we analyzed the 
electrodeposition process in the three electrochemical media: microemulsion (i.e., to obtain 
mesoporous nanorods), aqueous solution (i.e., to obtain compact nanorods) and an aqueous-
surfactant mixture (i.e., to understand the surfactant effect). It is possible electrodeposit CoNi 
from the three types of electrochemical media (Supporting Information) inside the 
nanochannels of polycarbonate (PC) membranes, which also allows the selection of the most 
adequate deposition potential in order to ensure the desired composition and deposition rate. 
The voltammetric study (see Supporting Information) of the CoNi system reveals a different 
voltammetric profile in presence of either the microemulsion or aqueous-surfactant mixture in 
respect to the classical profile in the aqueous solution. The first reduction peak occurred at 
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around − 0.6 V, assigned to the initial nickel deposition, followed by a primary reduction from 
− 0.8 V, assigned to the simultaneous codeposition of nickel and cobalt and a single oxidation 
peak, corresponding to the alloy oxidation in the anodic scan. However, with microemulsion, a 
lower j/E slope occurred due to the lower deposition rate in the more viscous microemulsion 
medium than in the aqueous solution. A similar Qox/Qred ratio in the voltammetric process 
reflects the dismal participation of hydrogen evolution in both media.  
The viscosity, surface tension and conductivity (Table 2S) of the three electrodeposition media 
were also measured to corroborate the possibility of filling the nanochannels of the PC 
membrane. From the voltammetric study, a deposition potential of -1,000 mV for the different 
electrochemical media with a relatively high deposition rate was selected, thereby ensuring 
comparable homogeneous growth comparable in three different systems in terms of efficiencies 
and alloy composition (Table 1S).  
Chronoamperometric curves of synthesis (Figure 2Sa) in stationary conditions evolved to quasi 
stationary values, which reflect a constant growth regime. The deposition rate was greater with 
compact nanorods (i.e., aqueous solution) due to the lower viscosity of the medium. Nanorods 
were released from the PC membrane and, after thorough washing, immersed in a gold solution, 
which resulting in the formation of a thin gold shell due to galvanic displacement. As scanning 
electron microscopy showed (Figure 2Sb and c) nanorods maintained their integrity after the 
formation of the Au shell, and nanorods of similar lengths (Figure 2Sc) and diameter emerged 
in both electrochemical media. Both type of nanorods exhibit similar composition before Au 
shell formation, which demonstrates that using electrodeposition with selected baths and 
conditions allows the preparation of CoNi nanorods with modulated composition. However, as 
Table 1 depicts, mesoporous nanorods contained a significantly more Au after the galvanic 
displacement, as could be expected due to their significantly greater area. 
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We characterized the morphology of the prepared nanorods by way of transmission electron 
microscopy (Figure 2), representative images of which reveal significant differences according 
to preparation approach. Nanorods obtained in aqueous solution displayed compact 
morphology and a diameter of 104 ± 9 nm, dispersion likely due to the insufficient uniformity 
of nanochannels in the PC membrane (Figure 2a). By contrast, IL/W microemulsions yielded 
mesoporous nanorods with a high density of well-defined nonspherical mesopores over the 
entire area, even at the inner part of the wires that formed an ordered, interconnected pore 
network with easy accessibility (Figure 2b). The diameter of the mesoporous nanorods was of 
107 ± 12 and the size of the mesopores approximately 2-4 nm. The average size of mesopores 
was coherent since ionic liquid droplets (hydrodynamic diameter = 12.4 nm; polydispersity 
index = 0.08) were slightly larger. This result is unsurprising, for pores are defined by the size 
of ionic liquid droplets, which should be smaller than the hydrodynamic diameter determined 
by DLS. X-ray diffractograms (Figure 4S) of both compact and mesoporous CoNi@Au 
nanorods show several peaks assigned to gold, given its presence in the shell and its significant 
diffracting response. Several peaks corresponding to the CoNi core were observed at 41.6, 47.5, 
76.1, 92.5, and 98.7 °2θ, which respectively correspond to the (100), (101), (110), (112), and 
(004) peaks of a Co hexagonal close-packed (hcp) crystalline phase, albeit slightly distorted 
due to the presence of Ni in the alloy. Other peaks of the Co hcp phase can be masked by gold’s 
diffraction peaks. A low proportion of a CoNi face-centered cubic (fcc) phase was detected at 
a peak of 51.6 °2θ. This primarily hcp crystalline structure has previously been obtained for 
CoNi films and nanorods. [18] Moreover, the selected area electron diffraction patterns of the 
synthesized nanorods (Figure 4Sa, b) can be also indexed as the (002), (101), (110) and (100) 
orientations of the distorted Co hexagonal close-packed structure.  
To use the nanorods synthesized as drug carriers, it is important to know the area that can 
effectively host pharmaceutical compounds. After covering them with the gold shell and 
recording the voltammetric response of the CoNi@Au nanorods in sulfuric acid, we therefore 
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calculated the electrochemical surface area of each nanorod type. The charge associated with 
the reduction of gold oxide (Figure 2c) was proportional to the highly active area of the gold 
surface. [19] We were also to confirm the complete formation of the Au shell over the entire area 
of both structures, since nanorods supported on a glassy carbon (GC) electrode were immersed 
in a H2SO4 0.5 M solutions for 5 minutes, after which a successive cyclic voltammetry was 
performed. CoNi nanorods were etched and dissolved when unprotected by the Au shell after 
5-min immersion in acidic media, which we verified by cyclic voltammetry that showed the 
response of the bare GC electrode. When the gold layer completely covered the nanorod, 
CoNi@Au was netter protected, even in H2SO4.  
In sum, for both compact and mesoporous nanorods, the typical profile of gold in sulfuric 
solution was obtained (Figure 2c), even despite a high number of scans (> 20). The 
voltammetric technique therefore allowed us to determine the immersion time that assures a 
complete gold layer on the surface of the nanorods. The stability of the CoNi@Au nanorods in 
the aggressive medium supposes their stability in a less aggressive (i.e., cellular) medium. The 
electrochemical surface area for both compact and mesoporous nanorods was 19 and 186 m2 g-
1, respectively, while their Au shell thickness (𝑆𝑇) was 0.7 and 0.1 nm, also respectively (Table 
1). The Au shell thickness can be calculated from the ECSA values as follows(𝐸𝑞. 1):  
𝑆𝑇 =
𝑉𝐴𝑢
𝑆𝐴𝑢
=  
(
𝑚𝑁𝑅 · 𝑃𝐴𝑢 
𝜌𝐴𝑢
)
𝐸𝐶𝑆𝐴 · 𝑚𝑁𝑅
=
𝑃𝐴𝑢 
𝐸𝐶𝑆𝐴 · 𝜌𝐴𝑢
         (𝐸𝑞. 1) 
where 𝑉𝐴𝑢 is the volume of Au shell, 𝑆𝐴𝑢 is the surface of Au shell, 𝑚𝑁𝑅  is the mass of one 
nanorod, 𝑃𝐴𝑢 (𝑔𝐴𝑢 𝑔𝐶𝑜𝑁𝑖@𝐴𝑢)⁄  is the weight percentage of Au of one nanorod, 
𝐸𝐶𝑆𝐴 (𝑚2 𝑔𝐶𝑜𝑁𝑖@𝐴𝑢)⁄  is the mass-normalized electrochemical surface area and 
𝜌𝐴𝑢 (𝑔𝐴𝑢 𝑐𝑚
3)⁄  is the density of gold.  
 
2.2.Nanorods functionalization and drug loading, magnetic properties and drug Release 
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2.2.1. Functionalization and drug loading. 
 Following the Au shell formation, the CoNi@Au nanorods were functionalized with HS-PEG 
or HS-PEG + CPT-11. First, the CoNi@Au-SH-PEG nanorods were used to detect the 
functionalization, whereas nanorods containing HS-PEG + CPT-11 were used to study the 
retention and release of the drug. Second, the CoNi@Au-SH-PEG nanorods were used to 
examine nanorods toxicity using HeLa cells, whereas the CoNi@Au-SH-PEG nanorods loaded 
with CPT-11 were used to investigate drug cytotoxicity delivered to HeLa cells via nanorod 
carriers. Lastly, CoNi@Au-SH-PEG nanorods, both with and without CPT-11, were also used 
to gauge HeLa cells’ uptake of nanorods by way of confocal microscopy.  
Functionalization was performed by immersion the nanorods in a solution of the nonpolar 
organic thiol with or without the selected drug in stirring conditions (800 rpm) for 48 h, chiefly 
to form a highly stable organic monolayer due to the strong gold-sulfur bonding. Figure 3a 
portrays the overall strategy of the functionalization with HS-PEG + CPT-11 (i.e., drug-loading 
scheme). The HS-PEG monolayer rendered the nanorod surface hydrophilic and minimizes the 
aggregation of the magnetic nanorods favoring its interaction with cells, as well as incorporated 
and retained CPT-11 inside the polymeric network and inside the interconnected pore network 
in mesoporous structures. We hoped that the retention of the drug in the organic network would 
labile enough to make release moderately easy. Following the functionalization, the 
nonsedimentation of the nanorods was observed for 7 days, which signifies significant 
improvement in the stability of the suspension fundamental for biomedical applications. The 
procedure also afforded the modification of the surface properties of the nanorods – for 
example, in terms of surface charge and specific recognition of nanorods.  
The formation and integrity of organic adsorbed layers onto the gold electrode was tested using 
voltammetric experiments, [13a] in which a close-packed layer of HS-PEG on the nanorod 
surface should hinder, if not block, the electrochemical superficial oxidation of the gold or the 
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reduction of gold oxide, as well as the oxidation or reduction of species in solution on the 
nanorod surface. Therefore, to verify nanorod functionalization with HS-PEG, we performed 
electrochemical probe experiments by recording cyclic voltammetries of the Fe (II)/Fe (III) 
system in both CoNi@Au and CoNi@Au-SH-PEG NRs (Figure 3b). To that end, a drop of 
nanorod suspension was placed on the surface of a GC substrate and dried to obtain each GC-
nanorod electrode. Figure 3b shows the typical reversible couple of the Fe (II)/Fe(III) system 
for the nonfunctionalized CoNi@Au nanorods. For the same amount of nanorods on the GC 
surface, the detected current was significantly greater for mesoporous nanorods, which 
corresponds to the far greater effective area. The presence of the PEG layer in the CoNi@Au-
SH-PEG nanorods caused a blocking effect of the surface of both mesoporous and compact 
CoNi@Au nanorods, thereby prompting a drastic decrease of the detected current. The 
electrochemical probe then allowed us to detect the functionalization of the nanorods with a 
HS-PEG layer. The faradaic Fe (II)/Fe (III) processes were strained with HS-PEG was on the 
nanorods, though the electrochemical processes were not entirely hindered, which reveals that 
some mass transport of the Fe (II)/Fe (III) redox species occurs in the presence of the HS-PEG 
layer to the nanorods surface. This finding is important because the mass transport of the drug 
to the entire bulk should also be possible for drug release.  
 
2.2.2. Magnetic properties of the functionalized nanorods.  
The magnetic properties of the CoNi@Au nanorods, both compact and mesoporous, were 
analyzed before and after their functionalization with HS-PEG molecules. Figure 4Sc shows 
the normalized M/Ms (M: magnetization) curves for the four types of nanorod. The response of 
the functionalized nanorods was highly similar to that of the nonfunctionalized ones, which 
indicates that the presence of HS-PEG molecules does not preclude the manipulation of the 
magnetic nanorods. Indeed, they can be easily retained or targeted by applying a magnetic field. 
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Compact CoNi@Au nanorods presented a soft-magnetic behavior, with a Mr/Ms=0.3 (Mr: 
remanence) and a coercivity Hc=230 Oe. Mesoporous CoNi@Au nanorods tended to exhibit 
superparamagnetic behavior, with low values for both remanence (Mr/Ms=0.1) and coercivity 
(Hc=50 Oe), a fact that favors their rapid response under an applied magnetic field and decreases 
their tendency to aggregate. In fact, both functionalized and nonfunctionalized mesoporous 
nanorods were easily maintained in suspension due to their magnetic properties and the low 
mass-per-volume of the unit.  
When a suspension of nanorods was subjected to the action of a rotating magnetic field, the 
nanorods readily commenced a circular motion, with a rotational speed according to the applied 
magnetic field. Therefore, the magnetic character of the synthesized nanorods allowed handling 
during washing, targeting and accumulation in a defined target site, and movement in 
suspension.  
 
2.2.3. Drug release.  
The In vitro drug retention and release were studied via spectrofluorimetric assay after the 
incubating both the compact and mesoporous nanorods with PEG (CoNi@Au-SH-PEG) and 
CPT-11. The comparison of the fluorescence of the CPT-11 in a 10 mM lactate buffered (pH 
4.4) solution before and after its incubation with the nanorods and the HS-PEG (i.e., nanorod 
cofunctionalization) demonstrated drug retention in the lattice of the HS-PEG molecules, for 
compact nanorods, and also in the interior of the pores, for mesoporous nanorods. The 
maximum yield of CPT-11 retention in mesoporous nanorods was of 76%, a significantly higher 
value than the 36% retention efficiency of the compact CoNi@Au-HS-PEG nanorods. 
Mesoporous nanorods exhibited an increased ability to accumulate the drug and thus higher 
retention efficiency. That result could be the expected, given their exceptionally high pore 
volume, which can accommodate the drug.   
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The magnetic properties of the synthesized and functionalized nanorods were studied regarding 
the CPT-11 release in static conditions, as well as under the influence of an external rotatory 
magnetic field (20 Hz). The aim of these assays was to assess whether the drug release was 
magnetic-dependent and thus the rate of release controllable. Figure 4a shows a diagram of the 
different release conditions considered in our work. Figure 4b-e show the release profiles of 
CPT-11 trapped in CoNi@Au-SH-PEG nanorods. Irinotecan-loaded nanorods were first 
washed 3 times with 1 mL of the lactate-buffered medium and placed in 1 mL of the same 
buffer, after which the release of the drug was measured for 25 h.   As Figure 4 shows, the 
release profiles of CPT-11 from compact and mesoporous nanorods, expressed as the 
percentage of the drug released, in static conditions and under the action of an external rotatory 
magnetic field, were highly similar. However, in absolute terms, significantly more CPT-11 
was released with mesoporous structures, as expected, due to its superior load capability. 
Therefore, by using the mesoporous nanorods, the amount of nanocarriers needed to deliver the 
same amount of drug can be significantly reduced. Moreover, the magnetic-dependent release 
of the drug allows the modulation and control of its release rate. As such, the increased 
efficiency of drug release coupled with the possibility of the remote manipulation of the 
nanorods, by applying direct magnetic fields, and their rotational manipulation, by applying 
rotating fields, underscores mesoporous and compact nanorods as promising nanocarrier for 
cancer therapy. Magnetic nanorods can be considered smart nanocarriers because they have 
been engineered to provide a vast array of properties, including the ability to respond to the 
externally applied stimuli.   
 
2.2.4. Cytotoxic activity of CPT-11 loaded CoNi@Au-SH-PEG NRs.  
The effectiveness of CPT-11-loaded CoNi@Au-SH-PEG nanorods was assessed and compared 
with that of the carrier (i.e., CoNi@Au-SH-PEG nanorods) by using the HeLa cell line. The 
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survival of the cells, incubated for 24 h with a fixed amount of CPT-11 (0.027 and 0.080 µmol 
of CPT-11for 20 µg mL-1 of compact and mesoporous nanorods, respectively), was evaluated 
24 h after CPT-11 was removed from the culture medium. HeLa cells were incubated in the 
same conditions with empty CoNi@Au-SH-PEG nanorods, largely to study the toxicity effect 
of the carrier. The toxicity studies carried out with both carriers (Figure 5Sa and b) showed 
that HeLa cells viability was greater than 90%, after incubation with empty compact and 
mesoporous CoNi@Au-SH-PEG nanorods, up to a concentration of 300 and 350 μg nanorods 
mL-1, respectively. From these results we chose a concentration of 20 μg nanorods mL-1 to study 
the toxicity of CPT-11 trapped in the nanorods. 
The cytotoxic effect of drug- loaded CoNi@Au-SH-PEG nanorods (Figure 5) was a function 
of the type of nanorod, either compact or mesoporous, and of the application, or not, of an 
external rotatory magnetic field. Cells were incubated 24 h with empty and CPT-11 loaded 
CoNi@Au-SH-PEG nanorods, and cell survival was evaluated by the tetrazolium dye (MTT) 
colorimetric assay 24 h after nanorod removal.  
When using empty nanorods, cell survival was greater than 90% in silent (0 Hz) conditions, 
whereas the application of an external rotatory magnetic field (20 Hz) for 30 min caused a 44% 
and a 37% decrease in cell survival for compact and mesoporous nanorods, respectively. Cell 
death in the absence of CPT-11 when applied in an external rotating magnetic field could be 
attributed to a possible localized heating or a rotation of the nanorods inside the cells.  
The incubation of HeLa cells with irinotecan-loaded compact and mesoporous CoNi@Au-SH-
PEG nanorods in silent conditions (0 Hz) prompted 15.4 % and 37.5% of cell death, 
respectively. This result was consistent with the amount of CPT-11 released in the absence of 
magnetic field from a same amount of compact (0.01 μmol CPT-11 per 20 μg nanorods) or 
mesoporous (0.033 μmol CPT-11 per 20 μg nanorods) nanorods.  
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When the external rotatory magnetic field (20 Hz) was applied, after incubating the HeLa cells 
with the same amount of nanorods in the medium of that used in the absence of the magnetic 
field, a significant increase of cell death was observed in both cases. In those conditions, cell 
death was of 52.8% and 83.7% when HeLa cells were incubated with CPT-11 loaded in 
compact or mesoporous CoNi@Au-SH-PEG nanorods, respectively. Such increased cell death 
can be attributed to the sum of two factors: the largest release of CPT-11 when the magnetic 
field was applied (0.027 μmol CPT-11 per 20 μg compact nanorods and 0.080 μmol CPT-11 
per 20 μg mesoporous nanorods) and the mechanical damage of cells due to the rotation of the 
nanorods inside the cells under the magnetic field effect.  
When these results are compared with those obtained when CPT-11 was administered in a 
liposomal form, it has been shown that both liposomes and CoNi@Au-SH-PEG nanorods have 
excellent ability to incorporate the drug or to release it under specific stimuli: hyperthermia for 
thermosensitive liposomes or a magnetic field for CoNi@Au-SH-PEG nanorods. [3b] However, 
based on results from this study, mesoporous CoNi@Au-SH-PEG nanorods significantly 
improve the therapeutic effectiveness of irinotecan for anticancer therapy, compared to that of 
liposomes and other mesoporous structures, including lipid–coated mesoporous silica 
nanoparticles. [20] That benefit derives from magnetic actuation, which radically enhances 
killing efficiency and provides easy manipulation, magnetic targeting, and better control of the 
drug release rate. We can hypothesize that mesoporous CoNi@Au-SH-PEG nanorods therefore 
constitute an interesting alternative to other more usual nanocarriers, like liposomes, to deliver 
different drugs. 
 
2.2.5. Nanorods uptake by HeLa cells.  
CellTrackerTM 5-chloromethylfluorescein diacetate (CMFDA) was used to demonstrate 
nanorod internalization by HeLa cells. CMFDA is a fluorescent chloromethyl derivative that 
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freely diffuses through the membranes of live cells. Once inside the cells, these mildly thiol-
reactive probes undergo what is thought to be a glutathion S-transferase-mediated reaction, in 
order to produce membrane-impermeable glutathion fluorescent dye adducts. A wide variety of 
applications were indicated for these dyes, including cell tracking in mixed cultures, long-term 
viability assays, and measuring cellular glutathione content using flow cytometry or the 
labelling of live cells. [21] 
The green probe CMFDA stained the entire HeLa cells body, shown in green in Figure 6, which 
also shows nanorods, in red, that were visualized by reflection. The images show that HeLa 
cells internalize both compact and mesoporous CoNi@Au-SH-PEG nanorods, though that 
some nanorods remain extracellular.  
The videos supplied (see Supporting Information) show the 3-dimensional reconstruction of 
alive HeLa cells with compact (Video 6S) and mesoporous (Video 7S) nanorods in their 
cytoplasm.   
 
3. Conclusion 
Electrochemical synthesis allowed us to prepare CoNi@Au-SH-PEG nanorods that 
demonstrated promise as magnetic nanocarriers for therapeutic molecules. Using aqueous 
solution allowed us to prepare compact, short (<2 microns) magnetic nanorods, whereas using 
ionic liquid-in-aqueous solution microemulsion allowed us to prepare mesoporous nanorods of 
similar dimensions and composition. The formation of a gold layer covering all of the nanorods, 
both compact and mesoporous,  allowed their functionalization with a long HS-PEG molecule, 
which conferred hydrophilic character to the nanorods, favored their maintenance in suspension 
during several days by decreasing their aggregation, allowed them to retain the selected drug 
(i.e., CPT-11), and allowed their gradual release. The mesoporous CoNi@Au-HS-PEG 
nanorods present advantages respect to the compact ones because they allow higher loading of 
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drug in the interior of the pores, a higher loading of drug retained in more HS-PEG molecules 
adsorbed on the nanorods with higher area/volume, easy magnetic manipulation due to their 
specific magnetic properties, a lesser tendency toward sedimentation due to their lower mass, a 
lesser toxicity of carriers, and greater cell death efficiency with fewer carriers. The magnetic 
character of the mesoporous nanorods moreover favored magnetic manipulation, magnetic 
targeting, and accumulation, as well as the mechanical death of cellules accompanying the death 
produced by the drug.  
 
4. Experimental Section 
Electrochemical media: The electrochemical media used to study the deposition process and to 
prepare nanorods were (i) an aqueous solution (W) of 0.2 M CoCl2 ·6 H2O (Carlo Erba > 98.0 %) + 0.9 
M NiCl2 (Panreac, > 98 %) + 30 g L
-1 H3BO3 (Merck, 99.8 %) + 0.7 g L
-1 saccharin (Merck, > 98%); (ii) 
an W + surfactant mixture (W+S) of  84.9 wt. % of W + 15.1 wt. % of p-octyl poly(ethylene glycol) 
phenyl ether a.k.a. Triton X-100 (S) (Acros Organics, 98 %); and (iii) ionic liquid-in-water (IL/W) 
microemulsions, prepared by mixing W, S and 1-butyl-3-methylimidazolium hexafluorophosphate a.k.a. 
bmimPF6 (C8H15F6N2P, Solvionic, 99 %) (IL) in proportions based on the literature (15.1 wt. % of S, 
1.1 wt. % of IL and 83.8 % of W). [19] The mixture was sonicated for 5 min under argon bubbling, which 
prompted transparent stable microemulsions. Droplet size and the polydispersity index of 
microemulsions were analyzed by dynamic light scattering (DLS) with Zetasizer Nano ZS 
(Malvern Instruments). 
Electrochemical synthesis and characterization: Electrochemical experiments were carried out 
using a microcomputer-controlled potentiostat/galvanostat Autolab with PGSTAT30 equipment and 
GPES software. As shown in the Supporting Information, the voltammetric study to find the optimum 
range of working potentials in aqueous (W), aqueous solution + surfactant (W+S) and ionic liquid-in-
water (IL/W) microemulsions systems was performed at room temperature (25 ºC), using a 3-electrode 
electrochemical system. Si / Ti (15 nm) / Au (100 nm) substrates (0.5 x 0.5 cm2), Pt spiral, and Ag / 
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AgCl / 3M KCl were used as working, counter, and reference electrodes, respectively.  To define the 
nanorods structure polycarbonate membranes (20-µm thick, 100 nm nominal pore diameter and 108 to 
2.5 109 pores cm-2 pore density with 100 nm-thick gold layer in one side, which enabled conductivity) 
were used as working electrodes.  After nanorod synthesis, the Au layer was removed by etching the Au 
using a saturated solution of I2/I
-, and under ultrasonic stirring, the PC membranes were dissolved with 
chloroform (x5), and  washed with chloroform (x10), ethanol (x5), and Millipore water (x5). Nanorods 
were also immersed in 0.1 M NaOH (x3) prior to being washed in Millipore water when microemulsions 
were employed. Lastly, after the cleaning procedure, a thin, nanometric shell of gold formed via galvanic 
displacement, which consisted of immersing in 2.9 mM of HAuCl4 solution.  
The morphology and structure of the CoNi@Au nanorods were examined by using transmission electron 
microscopy (Jeol 2100). Elemental composition was measured using electron probe microanalysis by 
energy-dispersive X-ray analysis (Cameca SX-50 equipment) or an X-ray analyzer incorporated in Leica 
StereoscanTM S-360 equipment. XRD patterns were registered by means of a Philips MRD 
diffractometer with parallel optical geometry using a Cu Kα radiation (λ=1.5418Å). The electrochemical 
surface area of the different prepared nanorods was obtained by integrating the charge associated with 
the reduction of gold oxide, which was proportional to the real active surface area of the gold surface, 
in cyclic voltammograms recorded in H2SO4.Electrochemical surface area were estimated assuming that 
the charge required to reduce gold oxide was 390 μC cm−2.[22] 
Nanorod functionalization and drug loading: Nanorods (900 µg ) were functionalized by immersion 
in 2 mL of nonpolar organic thiol (1.7 mM HS-PEG) with or without the selected drug (1.6 mM 
irinotecan hydrochloride - Afine Chemicals ,Hangzhou, China - which was pure, with a minimal grade 
of 99%.). Nanorod functionalization was corroborated by means of electrochemical probe experiments, 
namely by recording cyclic voltammetries of the Fe(II)/Fe(III) system in a KNO3 0.2 M + 2 mM 
K4[Fe(CN)6] + 2 mM K3[Fe(CN)6] solution. For each experiment, suspensions of functionalized and 
nonfunctionalized nanorods were dropped onto the surface of a GC electrode (Metrohm) rod of 0.0314 
cm2 and dried under nitrogen flow. Drug retention analysis was performed by fluorescence emission 
and excitation spectra (λex =278 nm) using an AMINCO-Bowman Series 2 spectrofluorometer with a 
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micro-cell (1 mL) at 25 ºC. To determine the concentration of drug released, a calibration curve was 
necessary, which involved comparing the unknown concentration to a set of standard samples of known 
concentrations.   
Cell culture:  Experiments were performed on the tumoral epithelial cell line HeLa originated from a 
cervix adenocarcinoma. HeLa cells were grown as monolayers in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 50 U mL-1 penicillin, 50 µg mL-1 streptomycin, 292 mg mL-1 L-glutamine, 
1% nonessential amino acids, and fetal bovine serum (FBS) at a final concentration of 10%; 4.5 g 
glucose L-1 (DMEM), fetal calf serum, penicillin-streptomycin, nonessential amino acids and L-
glutamine solutions were provided by from Biological Industries (Beit HaEmek, Israel). Cell cultures 
were performed in a humidified sterile atmosphere of 95% air and 5% CO2 at 37 °C in a SteriCult 200 
incubator (Hucoa-Erloss). HeLa cells were seeded in 25 cm2 flasks (90,000 cells), in 35 mm Petri dishes 
(25,000 cells) or in an 8 well NuncTM Lab-TekTM II Chambered Coverglass (Thermo Scientific, USA) 
for confocal microscope studies. Cells were grown for 72 h and treated when cultures achieved 
exponential growth. All sterile plastics were from Corning (Corning, NY, USA).  
Cells treatment: The effect of nanorods with and without CPT-11 upon cell survival in silent conditions 
(0 Hz) and in the external rotatory magnetic field (20 Hz) was determined. HeLa cells  seeded in 35 mm 
Petri dishes were cultured until reaching 70-75% confluence and incubated for 24 h with functionalized 
nanorods (20 µg nanorods  mL-1 DMEM), with and without CPT-11, in lactate buffer (10 mM pH 4.4). 
The cells were next washed 3 times with sterile Dulbecco´s phosphate buffered saline (PBS), 
supplemented with fresh medium and incubated for another 24 h in silent conditions. To test the 
influence of an external rotatory magnetic field, the magnetic field (20 Hz) was applied for 30 min after 
washing with PBS. Cell survival was evaluated after 24 h of postincubation in a fresh medium by MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay, which detected only living cells. 
[23] That assay was based on the reduction of tetrazolium salt to form a formazan dye using the electrons 
from the mitochondria of viable cells. The appropriate amount of a MTT stock solution (1 mg mL-1 
PBS) was added to DMEM for a final concentration of 47,6 μg mL-1. The medium without MTT was 
withdrawn and replaced by the medium supplemented with the dye. Cells were incubated for 3 h at 37ºC, 
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and to dissolve formazan precipitates, the medium was replaced by DMSO. Absorbance was measured 
at 526 nm on a Synergy H1 microplate spectrofluorimeter (SynergyMXTM, BioTek Instruments, 
Winooski, VT, USA). Cell survival was expressed as the percentage of absorption of treated cells in 
relation to that of control cells (100% survival).  
Confocal microscopy: Confocal microscopy was used to verify nanorods internalization. Cells were 
grown in an 8 well NuncTM Lab-TekTM II Chambered Coverglass. First, cells were incubated at 37ºC for 
18 h with a suspension of the corresponding CoNi@Au-HS-PEG nanorods in DMEM (20 µg nanorods 
mL-1) to allow their internalization. To confirm the intracellular localization of the nanorods, the 
cytoplasm of the cells was labeled with green CellTracker™ fluorescent probe CMFDA in serum-free 
culture medium, which acted as a cell tracker (C7025 Thermo Fisher, Life Technologies). The method 
of labeling consisted of five steps: (1) washing cells twice for 5 min with PBS, (2) incubating them for 
30 min at 37ºC with the binding solution (5μM CMFDA in serum-free culture medium), (3) washing 
them twice for 5 min with PBS, (4) incubating them for 30 additional min at 37ºC with supplemented 
cell culture medium, and (5) ultimately washing them twice for 5 min with PBS. After labeling, the cells 
were maintained in complete culture medium containing 10 mM HEPES to keep them alive during their 
observation with the microscope. HeLa cells were imaged using a Leica TCS SP2 confocal laser 
fluorescence microscope (Heidelberg, Germany) with simultaneous fluorescence and reflection 
acquisition, by using an argon laser of 488 nm. Different sections were initially scanned, and a data set 
of z-series images were collected from the bottom to top of the wells in the direction of the z-axis. Three-
dimensional reconstructions were made with Imaris 7.2.3 (Bitplane AG, Zurich, Switzerland).  
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Figure 1: Schematic representation of electrochemical synthesis of magnetic CoNi@Au NRs 
in aqueous solution and IL/W microemulsions. 
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Figure 2: Transmission electron micrographs of the magnetic compact (a) and mesoporous (b) 
CoNi@Au NRs. (c) Cyclic voltammetry (first cycle) of compact (A) and mesoporous (B) 
CoNi@Au NRs in H2SO4 0.5 M solutions at room temperature at the scan rate of 100 mV s
-1. 
Scale bar: 10 nm. 
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Figure 3: (a) Schematic representation of nanorod functionalization with HS-PEG and drug 
loading. (b) Cyclic voltammetries of the Fe (II)/Fe (III) system in a KNO3 0.2 M + K4[Fe(CN)6] 
2 mM + K3[Fe(CN)6] 2 mM solution on compact (blue lines) and mesoporous (green lines) 
CoNi@Au (continuous lines) and in CoNi@Au-SH-PEG nanorods (dashed lines) placed on 
glassy carbon electrodes, at room temperature and at scan rate of 100 mV s-1.  
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Figure 4: (a) Schematic representation of CPT-11 release from magnetic compact (left) and 
mesoporous (right) CoNi@Au nanorods loaded with the drug in static conditions (upper) and 
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under the influence of an external rotatory magnetic field of 20 Hz (bottom). (b - e) Influence 
of the application of the external rotatory magnetic field on CPT-11 release from compact (b, 
d) and mesoporous (c, e) CoNi@Au nanorods (450 µg) expressed as the μmol of CPT-11 
released (b, c) or as the percentage of the drug released (d, e) in static conditions (closed 
symbols) and under the influence of a magnetic external rotatory field (open symbols).  
 
 
Figure 5: Surviving fraction of HeLa cells incubated with CPT-11 (left) for 48 h with cell 
culture medium, to which a 100% survival control was assigned; (middle) with 20µg of empty 
compact (blue) or mesoporous (green) CoNi@Au-SH-PEG nanorods mL-1 in silent (0 Hz) and 
under a rotatory external magnetic field (20 Hz); and  (right) incubated with 20  µg of drug-
loaded compact (blue) or mesoporous (green) CoNi@Au-SH-PEG nanorods mL-1 in silent (0 
Hz) and under a rotatory external magnetic field (20 Hz). CPT-11 content in incubates was 
0.0013 or 0.0040 μmol µg-1, respectively, with compact and mesoporous nanorods. 
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Figure 6: Internalization of compact (left) and mesoporous (right) CoNi@Au-SH-PEG 
nanorods by HeLa cells; HeLa cells cytoplasm stained with 5-chloromethylfluorescein 
diacetate is shown in green, and nanorods visualized by reflection are marked in red. Images 
are representative of two independent experiments: a 3-dimensional reconstruction of HeLa 
cells (bottom) and sections of HeLa cells acquired during scanning (top). Scale bar: 20 µm. 
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Table 1: Working Potential, Deposition Charge, Length, Diameter, Elemental Composition, 
and Shell Thickness of Nanorods.  
 Potential / 
mV 
Deposition 
charge / C 
Length 
 / µm 
Diameter / 
nm 
Elemental 
composition / wt. 
% 
Shell 
Thickness / 
nm 
Co Ni Au 
Compact 
CoNi@Au 
- 1000 - 2.5 1.8 ± 0.4 104 ± 9 34 39 27 0.7 
Mesoporous 
CoNi@Au 
- 1000 - 2.5 1.7 ± 0.4 107 ± 12 29 31 40 0.1 
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A new versatile and simple procedure to grow magnetic mesoporous nanorods is 
proposed, by a first time, as magnetic drug nanocarriers with excellent drug-loading and 
improved therapeutic efficacy.  The nanostructures present low toxicity but when are loaded 
with a carcinogenic drug, induced cell death as a combination of both mechanical and drug 
death, making them excellent candidates for drug delivery. 
 
Keyword: drug delivery, mesoporous magnetic carriers, nanorods, microemulsions, 
irinotecan (CPT-11). 
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Cyclic voltammetries 
Voltammetric curves were recorded on Si / Ti (15 nm) / Au (100 nm) substrates (Figure 1S) in 
order to interpret the CoNi electrodeposition process in the microemulsion and to select the 
potentials able to form the CoNi mesostructures over gold surfaces. The blue curve (Figure 1Sa) 
corresponds to the typical profile of a CoNi deposition process in an aqueous solution: with the 
nucleation and the growth loop in the cathodic scan, and the oxidation peak corresponding to 
the alloy oxidation. When both surfactant and ionic liquid are added to the aqueous solution to 
form the microemulsion, the voltammetric profile changes. To justify this change, cyclic 
voltammetries of aqueous solution containing surfactant (Figure 1Sb) and of the microemulsion 
at different cathodic limits (Figure 1Sc) were recorded. The presence of the surfactant in the 
CoNi aqueous solution leads to a small reduction peak prior to the main alloy deposition current 
(Figure 1Sb, cathodic limit -0.8 V). We can assign this first reduction peak to the initial 
deposition of nickel or nickel-rich deposit, over which the anomalous codeposition of CoNi 
takes place. The presence of the surfactant hinders the adsorption of the Co (II) species proposed 
in the mechanism of the anomalous CoNi electrodeposition, [1] as the manner that the initial step 
of normal electrodeposition is detected.  
The voltammetries in the ionic liquid-in-CoNi aqueous solution microemulsion also shows a 
first reduction peak at around -0.6 V, assigned to the initial nickel deposition, followed by a 
main reduction peak assigned to the CoNi deposition. In the first reduction peak, the 
accumulation of deposit by means of a hold allows detecting the oxidation peak corresponding 
to the first nickel-rich deposit formed at potentials prior to the oxidation of the CoNi alloy.  
When deposits were prepared from the three electrodeposition media (CoNi aqueous solution -
W-, solution containing surfactant -W+S-, and IL/W microemulsion) the previous proposal is 
corroborated. In both W+S and IL/W systems, the obtained deposits at low deposition potentials 
(-650 mV) are nickel-rich, which is justified by the nobler character of this metal respect to the 
cobalt (Table 1S). At more negative potentials, the CoNi alloy is already formed, and 
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anomalous codeposition takes place, because the composition of the deposits are cobalt richer 
than that of the obtained in CoNi solution. In the case of the W system, the initial nickel 
deposition is not observed, as has been found previously. 
From the performed voltammetric study, we can select potentials equal or more negative than 
-900 mV to assure the formation of the CoNi alloy from the IL/W microemulsion. In order to 
obtain the same composition of the CoNi structures from aqueous solution W (compact 
structures) or IL/W microemulsion (mesoporous structures) over gold substrate, a potential of 
-1000 mV was selected to form the deposits. 
 
Table 1S: Elemental composition of CoNi deposits (1.6 C cm-2) on Si / Ti (15 nm) / Au (100 
nm) substrates prepared at different potentials in non-stirring conditions. 
 W W + S IL/W microemulsion 
Elemental 
Composition / wt. % 
-650 mV 
Co 
- 
7 ± 2 6 ± 1 
Ni 93 ± 2 94 ± 1 
-900 mV 
Co 45 ± 2 34 ± 2 30 ± 1 
Ni 55 ± 2 66 ± 2 70 ± 1 
-1000 
mV 
Co 49 ± 1 49 ± 3 49 ± 3 
Ni 51 ± 1 51 ± 3 51 ± 3 
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Figure 1S: Cyclic voltammetry under stationary conditions at 50 mV s-1 of (a) aqueous 
solution (blue line) and IL/W microemulsion (green line); (b) 84.9 wt. % of aqueous solution 
+ 15.1 of Triton X-100; and (c) IL/W microemulsion with (green line) and without (black 
line) Co(II) and Ni(II) species.  
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Conductivity, surface tension and viscosity of various electrochemical media  
 
Table 2S: Conductivity, surface tension and viscosity of the different electrochemical media: 
aqueous solution (W), aqueous solution + surfactant (W+S) and IL/W microemulsion.    
 W W + S IL/W microemulsion 
Conductivity / mS cm-1 104 77.7 67.9 
Surface Tension / mN m-1 75 32 32 
Viscosity / mPa s-1 1.43 11.1 37.5 
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Cronoamperometric curves, SEM characterization and length distribution of 
synthesized coni nanorods 
 
 
 
Figure 2S:  Chronoamperometric curves (a), SEM images (b, c) and length distribution (d) of 
CoNi NRs obtained at -1000 mV on PC membranes at 25 ºC in aqueous solution (blue) and 
ionic liquid-in-aqueous microemulsion (green). Scale bar: 100 nm. 
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X-Ray Diffraction 
 
 
 
 
Figure 3S:  XRD patterns for (a) compact and (b) mesoporous CoNi@Au nanorods.  
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Selected area electron diffraction patterns and magnetic properties 
 
 
 
Figure 4S:  Representative Selected Area Electron Diffraction (SAED) of compact (a) and 
mesoporous (b) CoNi@Au NRs. Room-temperature in-plane hysteresis loops of compact 
CoNi@Au (c and d, continuous blue line) and CoNi@Au-SH-PEG (c and d, dashed blue line) 
nanorods and mesoporous CoNi@Au (c and e, continuous green line) and CoNi@Au-SH-
PEG (c and e, dashed green line). Scale bar: 4 nm-1. 
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Cytotoxic activity of CoNi@Au-SH-PEG nanorods  
 
 
 
Figure 5S:  HeLa cell viability after incubation for 24 h with functionalized compact (a) and 
mesoporous (b) CoNi@Au-SH-PEG nanorods at the amounts indicated in the figure, followed 
by 24 h additional incubation with fresh culture medium.  
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Nanorods uptake by HeLa cells 
 
Video 6S. Three-dimensional reconstruction of alive HeLa cells containing compact nanorods 
in the cytoplasm, demonstrating the internalization of the carriers. See the attached video file 
for compact NRs.  
 
Video 7S. Three-dimensional reconstruction of alive HeLa cells containing mesoporous 
nanorods in the cytoplasm, demonstrating the internalization of the carriers. See the attached 
video file for mesoporous NRs.  
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